BioNTech Results Presentation Deck

COVID-19 vaccine development timeline DO COVID-19 mRNA Vaccine Program Initiation January 27, 2020 SARS-CoV-2 Genetic Sequence Made Public January 12, 2020 6 Collaborations Fosun Pharma: March 16, 2020 Pfizer: March 17, 2020 UU Candidate/ Dose Selection BNT162b2 July 24, 2020 Phase 1/2a Trial Germany Started April 23, 2020 • Up to 200 subjects aged 18-55 U.S. Started May 4, 2020 Up to 360 subjects aged 18-85 DI Initiated Pivotal Phase 2b / 3 Trial July 27, 2020 Start with up to 44,000 subjects UU FDA Fast Track designation July 13, 2020 Primary Efficacy Endpoint: To evaluate the efficacy of prophylactic BNT162b2 against confirmed COVID-19 in participants with (and without) evidence of infection before vaccination Initiated Rolling Submissions EMA: October 6, 2020 Canada: October 7, 2020 UK: October 9, 2020 Interim analysis finds evidence of efficacy November 9, 2020 Interim analysis finds more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection BIONTECH

View entire presentation